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Abstract 
Purpose: Ventilator associated‑lower respiratory tract infections (VA‑LRTIs), either ventilator‑associated pneumonia 
(VAP) or tracheobronchitis (VAT), accounts for most nosocomial infections in intensive care units (ICU) including. Our 
aim was to determine if appropriate antibiotic treatment in patients with VA‑LRTI will effectively reduce mortality in 
patients who had cardiovascular failure.
Methods: This was a pre‑planned subanalysis of a large prospective cohort of mechanically ventilated patients for at 
least 48 h in eight countries in two continents. Patients with a modified Sequential Organ Failure Assessment (mSOFA) 
cardiovascular score of 4 (at the time of VA‑LRTI diagnosis and needed be present for at least 12 h) were defined as 
having cardiovascular failure.
Results: VA‑LRTI occurred in 689 (23.2%) out of 2960 patients and 174 (25.3%) developed cardiovascular failure. 
Patients with cardiovascular failure had significantly higher ICU mortality than those without (58% vs. 26.8%; p < 0.001; 
OR 3.7; 95% CI 2.6–5.4). A propensity score analysis found that the presence of inappropriate antibiotic treatment was 
an independent risk factor for ICU mortality in patients without cardiovascular failure, but not in those with cardio‑
vascular failure. When the propensity score analysis was conducted in patients with VA‑LRTI, the use of appropriate 
antibiotic treatment conferred a survival benefit for patients without cardiovascular failure who had only VAP.
Conclusions: Patients with VA‑LRTI and cardiovascular failure did not show an association to a higher ICU survival 
with appropriate antibiotic treatment. Additionally, we found that in patients without cardiovascular failure, appropri‑
ate antibiotic treatment conferred a survival benefit for patients only with VAP.
Trial registry: ClinicalTrials.gov, number NCT01791530.
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Introduction
Lower respiratory tract infections (LRTIs) account for 
most nosocomial infections and patients admitted to 
intensive care units (ICUs) are at the highest risk, espe-
cially when invasive mechanical ventilation is provided 
[1, 2]. Ventilator-associated LTRI (VA-LRTI) comprises 
ventilator-associated pneumonia (VAP) and ventila-
tor-associated tracheobronchitis (VAT) [3–5]. VAP is 
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universally accepted with defined guidelines for diagno-
sis and treatment, but it is thought that VAT represents 
an intermediate process from colonization to VAP, leav-
ing its diagnosis and treatment under debate [6]. As an 
example, it remains controversial whether VAT should 
be treated with systemic antibiotics [7]. However, it is 
widely accepted that both VAP and VAT are associated 
with increased healthcare costs and are major drivers of 
antibiotic prescribing in the ICU [8, 9]. Notably, VAP is 
among the most common nosocomial infections in criti-
cally ill patients, with estimates of its incidence per 1000 
ventilator days being higher among patients with more 
comorbidities, such as the elderly and immunocompro-
mised [10], and varying considerably between countries.
The bacterial pathogens that cause VA-LRTI are fre-
quently multi-drug resistant (MDR), which negatively 
impacts patient’s outcome, because inappropriate antibi-
otic treatment is often prescribed [10, 11]. In an era of 
ever-increasing global antibiotic resistance and a dwin-
dling development of new antibiotic drugs, a healthcare 
crisis may be imminent. Indeed, as Dame Sally Davies, 
England’s Chief Medical Officer, said in a 2013 statement 
“…untreatable infection caused by antibiotic-resistant 
bacteria ‘poses a catastrophic threat’ to humans” and 
urged immediate global action [12]. However, the pres-
ence of resistant organisms and the use of inappropriate 
treatment are not the only independent risk factors for 
worse outcomes and mortality. The presence of cardio-
vascular failure has also repeatedly been shown to be an 
independent risk factor that may leave patients prone to 
worse clinical trajectories [13].
We hypothesized that appropriate antibiotic treat-
ment in patients with VA-LRTI will reduce mortality in 
patients with cardiovascular failure. The aim of this study 
was to determine if appropriateness of antibiotic treat-
ment was associated to a survival benefit in patients with 
cardiovascular failure and VA-LRTI.
Materials and methods
Study design and population
This was a pre-planned subanalysis of a large prospec-
tive cohort of 2960 critically ill patients who required 
mechanical ventilation for at least 48  h in eight 
countries in two continents. The base study was the 
Incidence and prognosis of VAT (TAVeM) study (Clini-
calTrials.gov, number NCT01791530) [3]. Data related 
to diagnostic techniques, antibiotics, and general popu-
lation characteristics have been published elsewhere 
[3, 14, 15]. Participating centers either received ethics 
approval from their institutions or ethics approval was 
waived (institutional review board number 2013515). 
Informed consent was waived, because of the observa-
tional nature of the study. Simplified Acute Physiology 
Score (SAPS) II scores were calculated on ICU admis-
sion (within the first 24 h), and Sequential Organ Fail-
ure Assessment (mSOFA) cardiovascular score was 
calculated at the time of VA-LRTI diagnosis (within 
the first 12  h). Patients with VA-LRTI diagnosis were 
analyzed based on the mSOFA cardiovascular score, to 
assess the presence of cardiovascular failure [16]. Car-
diovascular failure was defined as follows: patients with 
a mSOFA score of 4 (dopamine > 15 µg/kg/min OR epi-
nephrine > 0.1  µg/kg/min OR norepinephrine > 0.1  µg/
kg/min).
Definitions
A diagnosis of VA-LRTI was based on the presence of 
at least two of the following criteria: body tempera-
ture of more than 38.5  °C or less than 36.5  °C, leuco-
cyte count greater than 12,000 cells per μL or less than 
4000 cells per μL, and purulent endotracheal aspirate 
(ETA). Additionally, all episodes of VA-LRTI had to 
have a positive microbiological isolation in the ETA 
of at least  105 colony-forming units (CFU) per mL, or 
with bronchoalveolar lavage (BAL) of at least  104 CFU 
per mL, to be included in the final analysis. VAT was 
defined with the aforementioned criteria with no radio-
graphical signs of new pneumonia; VAP was defined by 
the presence of new or progressive infiltrates on chest 
radiograph. Anterior–posterior portable radiographs 
were reviewed either by the attending physicians or 
radiologist. In case of disagreement, a third physician 
was asked to interpret the radiograph; however, the 
final diagnosis and antibiotic treatment were at the dis-
cretion of the attending physician. No CT scans or lat-
eral radiographs were done for the diagnosis. We used 
serial chest radiographs to confirm new or persistent 
infiltrates as part of the diagnosis, but investigators 
were not masked to clinical characteristics, because 
of the observational nature of the study. In our study, 
we only included first episodes of microbiologically 
confirmed VA-LRTI occurring at more than 48 h after 
starting invasive mechanical ventilation. Resolution of 
either VAT or VAP was defined as the resolution of all 
diagnostic criteria. VAP was deemed as occurring sub-
sequently to VAT, if it was diagnosed at the 96 h period 
Take‑Home Message 
Appropriate antibiotic treatment is a major determinant of survival 
in patients with respiratory infections under mechanical ventila‑
tion. However, antibiotics appropriateness matters less in the most 
severe patients.
after diagnosis of tracheobronchitis and the same 
microorganism caused both the infections [17].
Microbiological identification and susceptibility tests 
were performed using standard methods. MDR patho-
gens were defined as those with acquired non-suscepti-
bility to at least one agent in three or more antimicrobial 
categories [18]. Antibiotics were considered appropri-
ate if the isolated pathogen was sensitive to at least one 
empirically prescribed antibiotic [13]. Immunocom-
promised patients were those with ongoing neoplasia, 
hematological malignancy, acquired immune deficiency 
syndrome (AIDS), allogeneic stem cell transplant, immu-
nosuppressive drugs, or organ transplant [15].
Endpoints
The main endpoint was ICU mortality according to the 
presence or absence of cardiovascular failure and with 
the appropriateness of antibiotic treatment.
Other additional objectives were to determine the asso-
ciation of ICU mortality in VAP and VAT based on the 
presence or absence of cardiovascular failure and the 
appropriateness of antibiotic treatment.
Statistical analysis
Data are expressed as medians with interquartile 
ranges (IQRs), unless specified otherwise. Comparisons 
between groups were performed with unpaired Student’s 
t test, one-way analysis of variance, Mann–Whitney U, or 
Kruskal–Wallis H tests for continuous variables depend-
ing on the data distribution. Chi-squared tests were used 
to compare categorical variables. Odds ratios (ORs) and 
confidence intervals (CIs) are reported where appro-
priate. In the present study, 2% (63/2960) of the eligible 
participants had at least one missing value for the set of 
variables considered relevant for the multivariate analy-
ses. The fractions of missing values in individual variables 
were low (0.0–3.7%). We used multiple imputation by 
chained equations (MICE) to replace missing values and 
generate multiple completed datasets [19].
For attributing to mortality analysis, we included all 
patients in the TAVeM database. We incorporated all 
variables from univariate analysis with p values that were 
less than 0.1 or were clinically relevant into the regression 
analyses as potential predictor variables [age, mSOFA 
and SAPS II score, appropriate antibiotics, MDR isolates, 
presence of either infection (VAT or VAP), and type of 
patient (i.e., medical, surgical, trauma)]. We included all 
these variables, plus chronic kidney disease, diabetes and 
immunosuppression, in the model used to calculate ICU 
mortality as the dependent variable. Linearity assump-
tion was tested for continuous covariates. To avoid 
overlap in the same regression model which could result 
in collinearity between the variables, logistic regression 
models, including each variable and baseline variables, 
were established and variables were selected using the 
backward stepwise regression method. We also calcu-
lated the Hosmer–Lemeshow goodness-of-fit (p = 0.25). 
Collinearity between variables was checked by inspecting 
the correlation between them and by looking at the cor-
relation matrix of the estimated parameters. The multi-
collinearity effect between risk factors in the model was 
detected using the variance inflation factor (VIF) and if 
VIF ≥ 5, excluded from the model. mSOFA was included 
in the model, but excluded from the final model due to 
collinearity. To account for center effects in this multi-
center study with a binary outcome, we fitted a general-
ized estimating equation model with a logit effect of the 
presence or absence of cardiovascular failure [20].
After this first approach, we generate a propensity 
score optimal matching analysis to determine the effect 
of appropriate antibiotic treatment and to control the 
potential confounding factors in the entire population 
with VA-LRTI (n = 689). Matching was done considering 
the following variables: Age, SAPS II, chronic kidney dis-
ease, diabetes, hematological malignancy, and admission 
type, because these variables did not have missing values 
and were considered clinically relevant to pair patients 
for the probability of receiving appropriate antibiotics 
[21, 22]. This approach allows us to study two compara-
ble (close to identical) cohorts: (1) Appropriate antibiotic 
treatment group and (2) control group, which comprise 
those patients who did not receive appropriate antibiotic 
treatment. We first use optimal matching with replace-
ment to compare outcomes between patients who have 
a similar distribution of all measured covariates. This 
method optimizes post-weighting balance of covariates 
between groups and, in this way, approximates the con-
ditions of random site-of-treatment assignment [23]. To 
assess our propensity score adjustment, we checked for 
adequate overlap in propensity scores for both groups 
with cross-validation model. After optimal matching, a 
regression model for ICU mortality was built to deter-
mine the effect of appropriate antibiotic treatment in 
LRTI. This model was adjusted for appropriateness of 
antibiotic treatment, presence of cardiovascular fail-
ure and their interaction. Finally, for simplicity, we per-
formed a simple logistic regression model in 689 patients 
with LRTI and assessed whether increasing mSOFA car-
diovascular scores, from 0 to 4, would modulate the asso-
ciation between antibiotic appropriateness and predicted 
mortality.
All analyses were performed using R project version 
3.4.0 with the tidyverse, randomForest, ggplot2, and 
AF.15 packages. p values of < 0.05 were considered signifi-
cant, unless stated otherwise.
Results
Among the initial cohort of 2960 patients, VA-LRTI 
occurred in 689 (23.2%). Among those with VA-LRTI, 
174 (25.3%) presented cardiovascular failure at the day 
of diagnosis (Fig.  1). The group with VA-LRTI and car-
diovascular failure were older, were more often medically 
admitted, had higher SAPS II scores on ICU admission, 
and presented with more organ failure (higher mSOFA) 
at the time of VA-LRTI diagnosis and more with immu-
nosuppression. Previous antibiotic use was associated to 
a higher presence of MDR pathogens (63.6% vs. 36.4%; 
p < 0.01; OR 1.8; 95% CI 1.1–2.9). Length of stay in ICU 
was significantly longer in patients with cardiovascular 
failure than in those without (Table  1). Cardiovascular 
failure was more frequent in patients with VAP than in 
those with VAT (35.8% vs. 13.1%; p < 0.001; OR 3.6; 95% 
CI 2.5–5.4).
ICU mortality was 30.8% (n = 912) in the total popu-
lation. Patients with VA-LRTI had a higher ICU mor-
tality than those without (34.7% vs. 29.6%; p < 0.01; 
OR 1.2; 95% CI 1.1–1.5). Patients with cardiovascu-
lar failure had significantly higher ICU mortality than 
those without (58% vs. 26.8%; p < 0.001; OR 3.7; 95% 
CI 2.6–5.4). Both for VAP (61.4% vs. 27.4%; p < 0.001; 
OR 4.2; 95% CI 2.6–6.6) and for VAT (47.6% vs. 26.3%; 
p < 0.01; OR 2.5; 95% CI 1.3–4.9) cardiovascular fail-
ure was associated with higher ICU mortality. Patients 
who received appropriate antibiotic treatment showed 
a lower ICU mortality compared to those who received 
inappropriate antibiotic treatment (87.8% vs. 80.3%; 
p < 0.01; OR 0.5; 95% CI 0.3–0.8). The use of appropri-
ate antibiotic treatment in the VAT group was asso-
ciated with a significantly lower progression to VAP 
either in patients with (18.2% vs. 55.6%; p < 0.03; OR 
0.1; 95% CI 0.1–0.8) or without cardiovascular failure 
(6% vs. 24.6%; p < 0.0001; OR 0.1; 95% CI 0.1–0.4). In 
Table 2 are displayed the risk factors analyzed for ICU 
mortality. Figure 2 shows the crude Kaplan–Meier sur-
vival curves of 90-day mortality according to the pres-
ence or absence of cardiovascular failure. Presence of 
cardiovascular failure was associated with increased 





































Fig. 1 Participant flow. VA-LRTI ventilator‑associated lower respiratory tract infection, CV cardiovascular, ICU intensive care unit, VAP ventilator‑asso‑
ciated pneumonia, VAT ventilator‑associated tracheobronchitis
Multivariate analysis of the data of patients with and 
without cardiovascular failure is shown in Table  3. A 
propensity score analysis was conducted and found that 
appropriateness of antibiotic treatment was associated 
with a survival benefit only in patients without cardio-
vascular failure (Fig.  3). Figure  4 shows the predicted 
probabilities for ICU mortality according to the sever-
ity of the cardiovascular mSOFA score at the onset of 
VA-LRTI. When the propensity score analysis was con-
ducted, only in patients without cardiovascular failure, 
the use of appropriate antibiotic treatment conferred 
a survival benefit for patients with VAP (p < 0.01; OR 
0.4; 95% CI 0.3–0.7). The exclusion of eight patients 
who died within 48 h of the VA-LRTI diagnosis did not 
change the results (supplement Fig. 1).
Discussion
The main finding of this subanalysis of a multicenter 
observational cohort study on VA-LTRI was that appro-
priate antibiotic treatment was not associated with a 
survival benefit in patients with cardiovascular fail-
ure. Additionally, we found that in patients without 
cardiovascular failure, appropriate antibiotic treatment 
conferred a survival benefit for patients with VA-LRTI 
who had VAP.
When we interpret the results from this study, we 
found that whereas appropriate antibiotic treatment in 
more severe patients such as those with cardiovascu-
lar failure manifested by a cardiovascular mSOFA score 
equal to 4 did not show any association to a better ICU 
survival, but in patients without cardiovascular failure, it 
would be perhaps better to wait for the microbiological 
results and provide an appropriate directed treatment, 
instead of starting an inappropriate empirical treatment 
[24]. Based on our findings, two questions remain open 
based on the observational design of the study. On the 
one hand, whether the presence of cardiovascular failure 
is per se the driver of outcome and therewith VA-LRTI 
is not a driver of mortality, as the patients already have 
an unfavorable outcome. On the other hand, in patients 
without cardiovascular failure, whether the presence 
of VA-LRTI can be of influence on the main outcomes. 
The timing of antibiotic administration in patients with 
sepsis has been a seemingly constant matter of debate 
[25]. Early recognition of sepsis and administration of 
antibiotics is considered crucial for its treatment by the 
Table 1 Patient characteristics by the presence or absence of cardiovascular failure
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range, LOS length of stay, MDR multi-drug resistant, 
SAPS Simplified Acute Physiology Score, SD standard deviation, mSOFA modified sequential organ assessment score, MDR multi-drug resistant, VA-LRTI ventilator-
associated lower respiratory tract infection, VAP ventilator-associated pneumonia, VAT ventilator-associated tracheobronchitis
No cardiovascular failure (n = 515) Cardiovascular failure (n = 174) p
Age (years), mean (SD) 58.6 (17.7) 61.67(17.2) 0.04
Male, n (%) 347 (67.4) 116 (66.7) 0.8
Admission type, n (%) < 0.001
 Medical 271 (52.6) 122 (70.1)
 Surgical 76 (14.8) 25 (14.4)
 Trauma 168 (32.6) 27 (15.5)
SAPS II score, mean (SD) 47.5 (15.0) 54.9 (18.1) < 0.001
mSOFA score, mean (SD) 6.2 (4.1) 11.3 (6.1) < 0.001
Barthel score, mean (SD) 79.4 (33.4) 84.8 (32.2) 0.06
Medical conditions, n (%)
 COPD 88 (17.1) 37 (21.3) 0.2
 CKD 46 (8.9) 23 (13.2) 0.1
 Diabetes mellitus 100 (19.4) 35 (20.1) 0.8
 Immunosuppression 30 (5.8) 25 (14.4) < 0.001
Previous antibiotic use, n (%) 431 (87.4) 156 (91.8) 0.2
Appropriateness, n (%) 436 (84.7) 151 (86.8) 0.5
MDR, n (%) 293 (56.9) 128 (73.6) < 0.001
VA‑LRTI, n (%)
 VAP, n (%) 237 (46) 132 (75.9) < 0.001
 VAT, n (%) 278 (54) 42 (24.1) < 0.001
ICU LOS (days), median (IQR) 20 (13–33) 28 (21–46) 0.2
Ventilator‑free days, median (IQR) 41 (31–47) 37 (32–49) 0.1
Surviving Sepsis Campaign (SSC) guidelines [26]. There 
is no general disagreement that patients in the most 
severe end of the spectrum (septic shock) should receive 
prompt antibiotic therapy [27], but questions remain for 
those individuals who are not that sick [28–30]. As only 
ICU mortality has been the scope of this study, other 
patient-centered outcomes related to appropriate anti-
biotic treatment might be further studied. We have to 
acknowledge that other outcome variables, beside ICU 
mortality, have important implications in current clini-
cal practice. When moving away from the fixed points of 
death, cost and quality of life outcomes, after both ICU 
and hospital discharge, are subject to increasingly diffi-
cult questions about their clinical relevance [31].
Ventilator-associated pneumonia prolongs the dura-
tion of mechanical ventilation and length of stay in the 
ICU, thereby contributing to the considerable economic 
burden associated with this condition [32]. The all-cause 
mortality rate for VAP is typically cited as being approxi-
mately 20–50% [33]. VAP has been associated with a 
higher crude ICU mortality rate. However, attributing 
mortality of VAP has been a matter of debate. Forel et al. 
found that in patients with ARDS whilst VAP increased 
crude ICU mortality, VAP was not found to be an inde-
pendent risk factor for ICU mortality [34]. On the other 
hand, in a systematic review published by Melsen et al., 
the attributed mortality of VAP was reported to be 13%, 
with higher rates for surgical patients and patients with 
Table 2 Risk factors for ICU mortality in patients with VA‑
LRTI
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ICU 
intensive care unit, MDR multi-drug resistant, SAPS Simplified Acute Physiology 
Score, SD standard deviation, mSOFA modified sequential organ assessment 
score, MDR multi-drug resistant, VA-LRTI ventilator-associated lower respiratory 
tract infection, VAP ventilator-associated pneumonia, VAT ventilator-associated 
tracheobronchitis
Alive (n = 450) Death (n = 239) p
Age, mean (SD) 56.6 (17.7) 64.3 (15.9) < 0.001
Male, n (%) 306 (62.9) 157 (61.5) 0.5
Admission type, n (%) 0.1
 Medical 233 (62) 160 (67.9)
 Surgical 66 (19.6) 35 (15.7)
 Trauma 151 (18.5) 44 (16.4)
SAPS II, mean (SD) 47.9 (17.9) 56.7 (18.5) < 0.001
mSOFA score, mean (SD) 7.7(3.7) 9.1(3.8) < 0.001
Barthel, mean (SD) 83.1 (30.8) 80.9 (30.4) 0.06
Medical conditions, n (%)
 COPD 74 (16.) 51 (21.3) 0.1
 CKD 27 (6) 42 (17.6) < 0.001
 Diabetes 78 (17.3) 57 (23.8) 0.04
 Immunosuppression 24 (5.3) 31 (13) <0.001
Appropriateness, n (%) 395 (87.8) 192 (80.3) < 0.01
MDR, n (%) 256 (56.9) 165 (69) 0.001
Cardiovascular failure, n (%) 73 (16,2) 101 (42.3) < 0.01
VAP 223 (49.6) 146 (61.1) < 0.001
Fig. 2 Kaplan–Meier curve for ICU mortality according to the presence (red)/absence (blue) of cardiovascular failure (p < 0.001 with log‑rank test). 
Abbreviations: ICU: intensive care unit
a mid-range severity scores at admission [35]. In our 
research, although medical patients showed a signifi-
cantly higher mortality in the multivariate analysis, this 
difference disappeared, when we adjusted for confound-
ers in the multivariate analysis. In previous studies, we 
demonstrated that VAT was not an independent risk fac-
tor for mortality unlike VAP [3]. We also wanted to assess 
if appropriate antibiotic treatment might be associated 
with survival benefit in patients with VA-LRTI and car-
diovascular failure [3, 14]. One could argue that VAT, per 
se, cannot be considered as a risk factor for cardiovascu-
lar failure, so we carefully evaluated every VAT episode 
to exclude potential confounders for cardiovascular fail-
ure manifested by a cardiovascular mSOFA. Therefore, 
based on our findings, we conclude that appropriate anti-
biotic treatment in the presence of cardiovascular fail-
ure did not affect mortality. This again opens the debate 
of whether treating VAT should be mandatory in every 
patient. In several observational studies, doing so offered 
no survival benefit. Currently, a randomized control trial 
(TAVeM2) is being conducted in France to determine if 
any VAT treatment can modify outcomes, specifically 
comparing the absence of therapy with short (3 days) and 
long (7 days) antibiotic courses [36].
We must acknowledge some limitations. First, this 
study was observational with an automatic selection of 
confounders and neither hospital mortality nor whether 
the presence of cardiovascular failure preceded or fol-
lowing the diagnosis of VA-LRTI was collected. VA-LRTI 
could be a complication of preceding cardiovascular 
failure with limited attributing mortality in itself, hence 
the lack of effect of antibiotics. Alternatively, however, 
cardiovascular failure could be the consequence of VA-
LRTI and identify a subgroup with increased mortal-
ity attributing to VA-LRTI despite the prescription 
of appropriate antibiotic treatment. Whilst we report 
appropriateness of antibiotic treatment, timing of treat-
ment, relevant dosage, and duration in compliance with 
guidelines were not collected and this represents a major 
limitation. The timing between diagnosis and treatment 
onset was not captured in the present database, preclud-
ing the use of current definitions of shock [37]. We there-
fore used cardiovascular failure as a surrogate of severity 
and we acknowledge that the presence of shock because 
of VAT is unlikely. Also, VAT is difficult to diagnose with-
out computed tomography, yet only X-rays were used for 
diagnosis in either VAT or VAP. However, strength of this 
study is that it is the largest prospective observational 
study to-date in this area of research and in addition, 
gathered data from centers in different countries and 
continents without exclusion criteria and with strict and 
well-defined diagnostic criteria for VAP and VAT.
Table 3 Multi‑variate analysis of  risk factors associated 
with  ICU mortality in  patients with  VA‑LRTI, according 
to the presence or absence of cardiovascular failure
A generalized estimating equation (GEE) model was fitted with a logit link, 
exchangeable correlation structure and non-robust standard errors. A country 
variable was included into the model to take into account potential country 
effects, however, it was not statistically significant (p = 0.22)
aOR adjusted odds ratio, CI confidence interval, CKD chronic kidney disease, 
COPD chronic obstructive pulmonary disease, MDR multi-drug resistant, OR 
odds ratio, SAPS Simplified Acute Physiology Score, VA-LRTI ventilator-associated 





aOR (95% CI) p value aOR (95% CI) p value
Age 1.0 (1.0–1.1) < 0.005 1.0 (0.9–1.0) 0.07
SAPS II 1.0 (0.9–1.1) 0.08 1.1 (0.9–1.1) 0.4
Admission type
 Medical (reference) 1.0 1.0
 Surgical 0.9 (0.7–1.1) 0.5 1.1 (0.7–1.5) 0.3
 Trauma 0.7 (0.5–0.9) 0.02 0.7 (0.5–1.3) 0.1
CKD 2.5 (1.2–4.8) < 0.005 2.1 (0.7–5.9) 0.2
MDR 1.6 (1.0–2.5) < 0.05 0.9 (0.4–1.9) 0.8
Appropriateness 0.5 (0.3–0.8) < 0.005 0.6 (0.2–1.8) 0.3
VAP 1.5 (1.1–2.3) 0.01 1.7 (0.7–1.9) 0.7
Fig. 3 Propensity score analysis to determine the association of 
appropriateness of antibiotic treatment and ICU mortality in patients 
with VA‑LRTI. A total of 408 patients (102 that received inappropriate 
antibiotic treatment and 306 that received appropriate antibiotic 
treatment). OR for inappropriate antibiotic treatment 1.97 (95% 
CI 1.17–3.317, p = 0.011); OR for shock 13.00 (95% CI 4.26–36.70, 
p < 0.001)
Based on our research, in patients with VA-LRTI and 
cardiovascular failure, appropriate antibiotic treatment 
was not associated to a higher ICU survival. On the other 
hand, we found that in patients without cardiovascu-
lar failure, appropriate antibiotic treatment conferred a 
survival benefit for patients with VA-LRTI who only had 
VAP.
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